免疫检查点阻断治疗伴或不伴淋巴结转移的黑色素瘤移行转移的多中心队列研究
该多中心回顾性队列研究纳入澳大利亚、欧洲和美国2015年1月至2020年12月间21家机构287例接受免疫检查点抑制剂治疗的黑色素瘤移行转移(伴或不伴淋巴结受累、无远处转移)患者。免疫治疗为一线者64例(22%),PD-1或CTLA-4单药分别为233例(81%)和23例(8%),联合治疗31例(11%)。总缓解率56%,完全缓解率36%,疾病进展率32%,中位无进展生存期10个月(95%CI 7.4-12.6个月),中位黑色素瘤特异性生存未达到。
要点
- 免疫检查点抑制剂治疗黑色素瘤移行转移的总缓解率为56%,完全缓解率为36%。
- 中位无进展生存期为10个月(95%CI 7.4-12.6个月),1年、2年、5年无进展生存率分别为48%、33%、18%。
- 中位黑色素瘤特异性生存未达到,1年、2年、5年黑色素瘤特异性生存率分别为95%、83%、71%。
核心结论
- 全身免疫治疗是黑色素瘤移行转移的有效治疗。
- 未来研究应在多模式治疗背景下评估全身免疫治疗的作用,包括手术、病灶内治疗和区域治疗等局部区域治疗。
研究设计与样本
- 多中心回顾性队列研究,纳入澳大利亚、欧洲和美国2015年1月至2020年12月间21家机构共287例患者。
- 患者为接受免疫检查点抑制剂治疗的黑色素瘤移行转移(伴或不伴淋巴结受累,AJCC8 N1c、N2c、N3c,无远处转移M0)。
- 治疗为PD-1抑制剂(纳武利尤单抗或帕博利珠单抗)和/或CTLA-4抑制剂(伊匹木单抗)。
- 疗效按修改版RECIST标准(针对皮肤病灶)评估。
主要发现
- 免疫治疗为一线治疗者64例(22%)。
- PD-1抑制剂单药治疗233例(81%),CTLA-4抑制剂单药治疗23例(8%),两者联合治疗31例(11%)。
- 总缓解率为56%,完全缓解率为36%,疾病进展率为32%。
- 中位无进展生存期为10个月(95%CI 7.4-12.6个月),1年、2年、5年无进展生存率分别为48%、33%、18%。
- 中位黑色素瘤特异性生存未达到,1年、2年、5年黑色素瘤特异性生存率分别为95%、83%、71%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease. The study aims to analyze the outcome of patients with ITM treated with ICI based on data from a large cohort of patients treated at international referral clinics. METHODS: A multicenter retrospective cohort study of patients treated between January 2015 and December 2020 from Australia, Europe, and the USA, evaluating treatment with ICI for ITM with or without nodal involvement (AJCC8 N1c, N2c, and N3c) and without distant disease (M0). Treatment was with PD-1 inhibitor (nivolumab or pembrolizumab) and/or CTLA-4 inhibitor (ipilimumab). The response was evaluated according to the RECIST criteria modified for cutaneous lesions. RESULTS: A total of 287 patients from 21 institutions in eight countries were included. Immunotherapy was first-line treatment in 64 (22%) patients. PD-1 or CTLA-4 inhibitor monotherapy was given in 233 (81%) and 23 (8%) patients, respectively, while 31 (11%) received both in combination. The overall response rate was 56%, complete response (CR) rate was 36%, and progressive disease (PD) rate was 32%. Median PFS was ten months (95% CI 7.4-12.6 months) with a one-, two-, and five-year PFS rate of 48%, 33%, and 18%, respectively. Median MSS was not reached, and the one-, two-, and five-year MSS rates were 95%, 83%, and 71%, respectively. CONCLUSION: Systemic immunotherapy is an effective treatment for melanoma ITM. Future studies should evaluate the role of systemic immunotherapy in the context of multimodality therapy, including locoregional treatments such as surgery, intralesional therapy, and regional therapies.
引用
- Holmberg CJ, Ny L, Hieken TJ, et al. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. Eur J Cancer. 2022. PMID: 35644725. doi:10.1016/j.ejca.2022.03.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。